Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
478.62
-9.64 (-1.97%)
At close: Feb 10, 2026, 4:00 PM EST
478.83
+0.21 (0.04%)
After-hours: Feb 10, 2026, 4:13 PM EST
Madrigal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 13 analysts that cover Madrigal Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $631.46, which forecasts a 31.93% increase in the stock price over the next year. The lowest target is $405 and the highest is $964.
Price Target: $631.46 (+31.93%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Madrigal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 9 | 8 | 8 |
| Buy | 2 | 3 | 4 | 4 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 12 | 13 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Initiates $964 | Buy | Initiates | $964 | +101.41% | Jan 28, 2026 |
| Citizens | Citizens | Buy Maintains $527 → $745 | Buy | Maintains | $527 → $745 | +55.66% | Jan 20, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $540 → $900 | Buy | Maintains | $540 → $900 | +88.04% | Dec 19, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $560 → $670 | Strong Buy | Maintains | $560 → $670 | +39.99% | Dec 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $568 → $620 | Strong Buy | Maintains | $568 → $620 | +29.54% | Nov 21, 2025 |
Financial Forecast
Revenue This Year
964.47M
from 180.13M
Increased by 435.42%
Revenue Next Year
1.49B
from 964.47M
Increased by 54.39%
EPS This Year
-10.95
from -21.90
EPS Next Year
1.05
from -10.95
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.0B | 1.6B | ||||
| Avg | 964.5M | 1.5B | ||||
| Low | 889.8M | 1.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 456.8% | 68.9% | ||||
| Avg | 435.4% | 54.4% | ||||
| Low | 394.0% | 24.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -9.29 | 9.35 | ||||
| Avg | -10.95 | 1.05 | ||||
| Low | -14.45 | -6.84 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.